SCHEMBL2274239

SCHEMBL2274239

CC(Cl)C(=O)Nc1c(NC(=O)CCl)ccc2c1C(=O)c1ccccc1C2=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 6/20 0.43
MAPT P10636 5/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
MAPK1 P28482 3/20 0.43
PKM P14618 2/20 0.43
KDM4E B2RXH2 2/20 0.43
MMP14 P50281 1/20 0.43
MAOA P21397 1/20 0.43
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
ALDH1A1 P00352 3/20 0.42
POLB P06746 2/20 0.42
GAA P10253 1/20 0.42
DNMT1 P26358 1/20 0.42
RAD52 P43351 1/20 0.42
SMARCA2 P51531 1/20 0.42
NPSR1 Q6W5P4 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
NSD2 O96028 1/20 0.39
BLM P54132 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12393966 0.90 SMN1; SMN2 (0.47) TERTMAPTSMN1; SMN2MAPK1PKM
SCHEMBL2267954 0.84 TERT (0.47) TERTMAPTSMN1; SMN2MAPK1PKM
SCHEMBL2272366 0.83 CYP1A2 (0.51) TERTMAPTSMN1; SMN2MAPK1PKM
SCHEMBL2269177 0.82 CASP3 (0.48) TERTMAPTSMN1; SMN2MAPK1PKM
SCHEMBL2267203 0.82 TERT (0.45) TERTMAPTSMN1; SMN2MAPK1PKM
SCHEMBL2274854 0.81 ALDH1A1 (0.55) TERTMAPTSMN1; SMN2MAPK1PKM
SCHEMBL2269050 0.81 ALDH1A1 (0.44) TERTMAPTSMN1; SMN2MAPK1PKM
SCHEMBL2268488 0.81 MAPT (0.50) TERTMAPTSMN1; SMN2MAPK1PKM
SCHEMBL7089473 0.81 MAPT (0.50) TERTMAPTSMN1; SMN2MAPK1PKM
SCHEMBL2274338 0.80 CASP3 (0.46) MAPTSMN1; SMN2MAPK1PKMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8530465-B2 1, 2-disubstituted amido-anthraquinone derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2013-09-10 US claimed
US-20130059862-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof HUANG HSU-SHAN (TW) 2013-03-07 US claimed
US-8530465-B2 1, 2-disubstituted amido-anthraquinone derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2013-09-10 US disclosed
US-8530465-B2 1, 2-disubstituted amido-anthraquinone derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2013-09-10 US disclosed
US-20130059862-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof HUANG HSU-SHAN (TW) 2013-03-07 US disclosed
US-20130059862-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof HUANG HSU-SHAN (TW) 2013-03-07 US disclosed
US-8304415-B2 1, 2-disubstituted amido-anthraquinone derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2012-11-06 US disclosed
US-20110207739-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207739-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof ANXA1, ANXA5, ANXA2 TERT 3768/4885MAPT 4724/4885SMN1; SMN2 3794/4885
US-20130059862-A1 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof ANXA5, ANXA1, HCCS TERT 3263/4885MAPT 4820/4885SMN1; SMN2 4307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.